FGFR2

Tyra Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Investor, Fibroblast growth factor receptor 1, Nasdaq, Cancer, SNP, Webcast, Fibroblast growth factor receptor, Chromosomal rearrangement, CA, FGFR4, Transfection, Company, Science, Conference, FGFR, Patient, CEO, FGFR3, Achondroplasia, FGFR2, RET, Pharmaceutical industry, Security (finance), Cholangiocarcinoma

Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.

Key Points: 
  • Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
  • Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers.

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

Retrieved on: 
Thursday, November 3, 2022
Patient, FGFR2, Waltham, Potent, Society, GIST, GLOBE, Adult, Webcast, Mastocytosis, CO, Mutation, ASH, KIT, Nasdaq, Novel, Myeloproliferative neoplasm, B cell, HER2/neu, Pharmaceutical industry, Apex

and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022.

Key Points: 
  • and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022.
  • Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
    Session Name: 634.
  • KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.
  • In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2.

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, November 3, 2022
ORR, Private Securities Litigation Reform Act, FGFR2, Hyperphosphatemia, Investment, HR, GLOBE, ESMO, D, Safety, Fulvestrant, Fourth grade, Toxic leukoencephalopathy, COVID-19, Nasdaq, Therapy, Research, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Risk, Diarrhea, Compte rendu, Security (finance), CCA, Patient, Drug discovery, Pharmaceutical industry, Dynamo

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2022 financial results and recent corporate highlights.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2022 financial results and recent corporate highlights.
  • We continue to deliver on our execution focus for 2022 and the third quarter uniquely exemplified this, said Sanjiv Patel, M.D., Relay Therapeutics president and chief executive officer.
  • Relay Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into 2025.
  • G&A Expenses: General and administrative expenses were $16.1 million for third quarter of 2022, as compared to $14.7 million for the third quarter of 2021.

Tyra Biosciences Announces Planned Chief Financial Officer Transition

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Agricultural economics, Growth, Montana State University, FGFR3, Risk, CEO, Vinylcyclopropane rearrangement, Fibroblast growth factor receptor, MicroRNA, Acquisition, U.S. Securities and Exchange Commission, Annual report, Daiichi Sankyo, FGFR, SEC, Cancer, Esperies, Research, AbbVie, FGFR4, Regeneron Pharmaceuticals, Business administration, Esperion Therapeutics, IND, Nasdaq, COVID-19, FGFR2, Agriculture, Fibroblast growth factor receptor 1, Eli Lilly, SNP, CFO, Form 10-K, RET, Sale, PricewaterhouseCoopers, Private Securities Litigation Reform Act, Achondroplasia, Transfection, Therapy, FDA, Patient, Audit committee, Cooper, Science, CA, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022. TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition. 

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
  • TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition.
  • Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
  • "It has been my privilege to serve as Chief Financial Officer of TYRA since shortly after the company's inception," said Ms. van den Boom.

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

Retrieved on: 
Wednesday, October 26, 2022
Pharmacokinetics, SEC, ENA, Waltham, Private Securities Litigation Reform Act, Nasdaq, Forward-looking statement, KIT, B cell, HER2/neu, Poster, Annual report, Patient, EORTC, Risk, EGFR, FGFR2, GLOBE, CO, Mutation, Cancer, GIST, Vaccine, Pharmaceutical industry, Cogent

and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR ("ENA") annual meeting to be held October 26-28, 2022.

Key Points: 
  • and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR ("ENA") annual meeting to be held October 26-28, 2022.
  • The preclinical data presented today highlight an update on two of the first programs undertaken by the Cogent Research Team, said Andrew Robbins, Cogents President and Chief Executive Officer.
  • Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation

Retrieved on: 
Saturday, October 22, 2022
MSCI, BB Biotech, Cardiomyopathy, SMIM, Insurance, Net asset value, Inflation, Health care, Therapy, Growth, APOLLO, TTR, Pfizer, NBI, Severe acute respiratory syndrome coronavirus 2, Part, Patient, Cholangiocarcinoma, RNA, CHF, ETF, KRAS, Vitiligo, Medicare Part D, Sirna, Medicare, FGFR2, Obesity, Legislation, Pain, Conditional sentence, Clinical trial, IRA, Alzheimer's Drug Discovery Foundation, COVID-19, Biotechnology, Endometriosis, Amyloidosis, NAV, BB, Leadership, Pharmaceutical industry, Health insurance, Radius, Ionis, EUR, Alnylam Pharmaceuticals, USD

BB Biotech shares ended the quarter with a negative return of 6.9% in CHF and 4.7% in EUR.

Key Points: 
  • BB Biotech shares ended the quarter with a negative return of 6.9% in CHF and 4.7% in EUR.
  • In the eyes of BB Biotech's Investment Team, the biotech sector is attractively valued and offers attractive investment opportunities.
  • BB Biotech believes that the legislation, if it is maintained, will spur innovation so that winners emerge in a more competitive and price-sensitive environment.
  • The quarterly report of BB Biotech AG as at September 30, 2022 can be downloaded at report.bbbiotech.ch/Q322 or www.bbbiotech.com .

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008

Retrieved on: 
Monday, September 12, 2022
Oncology, Health, Medical Devices, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CCA, American Securities, European Society for Medical Oncology, Liquid, Twitter, FDA, Cholangiocarcinoma, TMB, Publication, LinkedIn, FGFR, Population, Gene, Foundation Medicine, Therapy, FGFR2, Patient, Clinical trial, Nucleic acid thermodynamics, Cancer, Physician, Prognosis, Protein, Oncology, Nasdaq, Family, Microsatellite instability, Relay, Research, DNA, Congress, MSI, Preclinical development, Multimedia, Biopsy, Drug discovery, Plasma, ESMO, Pharmaceutical industry, Medical imaging, Medical device

Were proud to partner with the leader in companion diagnostic approvals as we work to advance this potentially life-changing therapy and create access to it once approved.

Key Points: 
  • Were proud to partner with the leader in companion diagnostic approvals as we work to advance this potentially life-changing therapy and create access to it once approved.
  • The oral presentation from the ESMO Congress for RLY-4008 is available on the Relay Therapeutics website under Publications: https://relaytx.com/publications/ .
  • Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research.
  • Relay Therapeutics initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

Retrieved on: 
Sunday, September 11, 2022
CCA, Precision medicine, European Society for Medical Oncology, Therapy, FGFR2, Patient, Clinical trial, ORR, Oncology, Nasdaq, GLOBE, Congress, ESMO, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 11, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced late breaking interim clinical data in an oral presentation for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), in a global phase 1/2 clinical trial in patients with FGFR2-altered CCA and multiple other solid tumors. The interim data presented today at the European Society for Medical Oncology (ESMO) Congress demonstrate an 88% overall response rate (ORR) at the pivotal dose of RLY-4008, 70 mg once daily (QD), as of August 1, 2022, and further support our hypothesis that selective inhibition of FGFR2 can improve the treatment for patients with FGFR2-driven tumors.

Key Points: 
  • We believe the interim ORR of 88% for these patients helps to demonstrate the potential power of our Dynamo platform to build transformative therapies for patients.
  • Additionally, we continue to generate clinical data outside of CCA and anticipate sharing them in 2023.
  • Thank you to the patients, investigators and clinical trial teams who participate in clinical trials of our investigational therapies.
  • The data presented at the ESMO Congress were based on an August 1, 2022 data cut-off date from both the dose escalation and dose expansion phases of the trial.

Tyra Biosciences to Participate at September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022
CA, Achondroplasia, Cancer, Fibroblast growth factor receptor 1, SNP, FGFR, Fibroblast growth factor receptor, RET, LinkedIn, Science, FGFR4, Chromosomal rearrangement, Nasdaq, Transfection, FGFR2, FGFR3, Patient, Medical imaging, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:
    Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • Leveraging SNP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.
  • TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers.

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

Retrieved on: 
Monday, September 5, 2022
European Society for Medical Oncology, Investigational New Drug, COVID-19, CA, Security (finance), CEO, Achondroplasia, Cancer, MTD, Research, Form 10-K, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibroblast growth factor receptor 2, SNP, FGFR, Fibroblast growth factor receptor, Risk, FGFR3, RET, Hyperphosphatemia, FGFR1, Food, ESMO, LinkedIn, Science, SEC, Time-invariant system, Vinylcyclopropane rearrangement, U.S. Securities and Exchange Commission, Nasdaq, Company, FDA, Oncology, Transfection, FGFR2, Congress, Annual report, Private Securities Litigation Reform Act, Trial of the century, Patient, Pharmaceutical industry, Cholangiocarcinoma

"We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.

Key Points: 
  • "We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.
  • Details of the poster presentation are as follows:
    Regular abstracts will be published on the ESMO website on September 5, 2022.
  • The poster presentation on TYRA-300 will be made available on the TYRA website under the "For Investors" section on September 12, 2022.
  • TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.